KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
KBIO was delisted on the 16th of December, 2015.
46 hedge funds and large institutions have $89.1M invested in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 12 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
1% more capital invested
Capital invested by funds: $87.9M → $89.1M (+$1.15M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 50 → 46 (-4)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$3.06M |
| 2 |
JP Morgan Chase
New York
|
+$969K |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
+$522K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$347K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$258K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.29M |
| 2 |
LBH
Lehman Brothers Holdings
New York
|
-$1.19M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.13M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$565K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$565K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BG
51
BlackRock Group
London,
United Kingdom
| – | -$159K | -4,395 | Closed |
|
|
LOM
52
Loeb Offshore Management
New York
| – | -$69K | -1,903 | Closed |
|
|
U
53
UBS
Zurich,
Switzerland
| – | -$5K | -148 | Closed |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| – | -$4K | -110 | Closed |
|
55
Ameriprise
Minneapolis,
Minnesota
| – | -$2K | -68 | Closed |
|
56
AllianceBernstein
Nashville,
Tennessee
| – | -$2K | -63 | Closed |
|
KBIO Hedge Fund Activity: Q4 2013 in Review
46 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) for Q4 2013, worth a combined $89.1M — up 1.3% from $87.9M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of KBIO and 8 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 19 added.
The largest buyer was UBS AM, adding an estimated $3.06M. The largest seller was Fidelity Investments, cutting an estimated $1.29M.
- 46 institutional investors held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) as of Q4 2013, down from 50 in Q3 2013.
- Funds reported $89.1M of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) stock for Q4 2013, up 1.3% quarter-over-quarter.
- 8 funds opened new KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) positions in Q4 2013 and 12 closed out, a net change of -4 holders.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) buyer in Q4 2013 was UBS AM, an estimated $3.06M added.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) seller in Q4 2013 was Fidelity Investments, an estimated $1.29M sold.
Based on aggregated 13F filings for Q4 2013.